An effective early death scoring system for predicting early death risk in de novo acute promyelocytic leukemia

References

• Lou Y, Ma Y, Sun J, et al. Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia. Ann Hematol. 2017;96(11):1793–1800.
   PubMed Web of Science ®Google Scholar
• Hassan IB, Zaabi MRA, Alam A, et al. Characteristics features and factors influencing early death in acute promyelocytic leukemia; Experience from United Arab Emirates (UAE). Int J Hematol. 2017;106(1):90–98.
   PubMed Web of Science ®Google Scholar
• Mantha S, Goldman DA, Devlin SM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129(13):1763–1767.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res. 2010;125 Suppl (2):S51–S54.
   PubMedGoogle Scholar
• Naymagon L, Moshier E, Tremblay D, et al. Predictors of early hemorrhage in acute promyelocytic leukemia. Leuk Lymphoma. 2019;60:2394–2403.
   PubMed Web of Science ®Google Scholar
• Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand. 2009;159(3):189–194.
   Google Scholar
• Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469–3473.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Deneberg S, Antunovic P, et al. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013. Leukemia. 2017;31(6):1457–1459.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang S, Zhang Y, et al. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide. Ann Hematol. 2017;96(12):2005–2013.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhao Y, Zhang Y, et al. Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia. Ann Hematol. 2018;97(3):409–416.
   PubMed Web of Science ®Google Scholar
• de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–3402.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hou W, Wang P, et al. Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death. Cancer Manag Res. 2018;10:3619–3627.
   PubMed Web of Science ®Google Scholar
• Lou Y, Ma Y, Suo S, et al. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leuk Res. 2015;39(9):938–944.
   PubMed Web of Science ®Google Scholar
• Song YH, Qiao C, Xiao LC, et al. Hyperfibrinolysis is an important cause of early hemorrhage in patients with acute promyelocytic leukemia. Med Sci Monit. 2018;24:3249–3255.
   PubMed Web of Science ®Google Scholar
• Lou Y, Lu Y, Zhu Z, et al. Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy. Hematol Oncol. 2018;36(3):584–590.
   Web of Science ®Google Scholar
• Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78(3):213–219.
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–1254.
   PubMed Web of Science ®Google Scholar
• Abrahao R, Ribeiro RC, Medeiros BC, et al. Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. Cancer. 2015;121:3990–3997.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F. ED in APL: tip of the iceberg?. Blood. 2011;118(5):1188–1189.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–1253.
   PubMed Web of Science ®Google Scholar
• Sobas M, Rodriguez-Veiga R, Vellenga E, et al. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. Eur J Haematol. 2020;104:162–169.
   PubMed Web of Science ®Google Scholar
• Cao Y, Yao L, Liu Y, et al. An atypical PML-RARA rearrangement resulting from submicroscopic insertion of the RARA gene at the PML locus with novel breakpoints within PML Exon 7b and RARA Exon 3. Acta Haematol. 2019;142(2):98–104.
   PubMed Web of Science ®Google Scholar
• Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018;32(2):89–95.
   PubMed Web of Science ®Google Scholar
• Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004–1009.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Fisher SI. Prompt all-trans retinoic acid administration and early death in acute promyelocytic leukemia: what does the evidence say?. Leukemia. 2014;28(12):2425–2426.
   PubMed Web of Science ®Google Scholar
• Chamoun K, Kantarjian HM, Wang X, et al. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019;125(18):3219–3224.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014;123(18):2777–2782.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128–1134.
   PubMed Web of Science ®Google Scholar